Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

BACKGROUND: High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of patients, we investigated both tumor biopsies and peripheral blood leukocytes (PB...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Gharbaran, Rajendra, Goy, Andre, Tanaka, Takemi, Park, Jongwhan, Kim, Chris, Hasan, Nafis, Vemulapalli, Swathi, Sarojini, Sreeja, Tuluc, Madalina, Nalley, Kip, Bhattacharyya, Pritish, Pecora, Andrew, Suh, K Stephen
Format:	Artigo
Sprog:	Inglês
Udgivet:	BioMed Central 2013
Fag:	Research
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3766006/ https://ncbi.nlm.nih.gov/pubmed/23988031 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-62
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

Lignende værker